



26,000 Results Any time ▾

A systematic review on the safety and efficacy of yttrium ...

<https://www.ncbi.nlm.nih.gov/pubmed/24318568>

A systematic review on the safety and efficacy of yttrium-90 radioembolization for unresectable, chemorefractory colorectal cancer liver metastases. The median time to intra-hepatic progression was 9 months (range 6-16). The median overall survival was 12 months (range 8.3-36). The overall acute toxicity rate ranged from 11 to 100% (median 40.5 %).

Cited by: 75 Author: Akshat Saxena, Lourens Bester, Leonard...

Publish Year: 2014

A systematic review of yttrium-90 radioembolization for ...

<https://www.sciencedirect.com/science/article/pii/S0720048X17301845>

90Y radioembolization is a form of intra-arterial brachytherapy that has emerged as a promising treatment option for unresectable liver metastases of melanoma [12], [13], [14]. However, there is still a need to systematically evaluate the outcomes of 90Y radioembolization in these patients.

Cited by: 2 Author: Zhongzhi Jia, Guomin Jiang, Chunfu Zhu, ...

Publish Year: 2017

Yttrium-90 radioembolization for unresectable metastatic ...

<https://www.sciencedirect.com/science/article/pii/S0720048X18300093>

90Y radioembolization can be used as an alternative therapy for unresectable liver metastases of NETs, with an improved survival rate and tumor response. This treatment is also effective for patients who have undergone unsuccessful TAbE/TACE therapy and for the relief of symptoms in patients with carcinoid syndrome.

Cited by: 5 Author: Zhongzhi Jia, Weiping Wang

Publish Year: 2018

Yttrium-90 Radioembolization of Hepatic Metastases from ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4110696>

Jul 25, 2014 · Yttrium-90 radioembolization as a salvage treatment for chemotherapy-refractory disease. A recent systematic review by Saxena et al. (n = 979) reported a median time to intrahepatic progression of 9 months and a median overall survival of 12 months, the overall acute toxicities ranged from 11 to 100%...

Cited by: 17 Author: Mihir Raval, Dinesh Bande, Dinesh Bande...

Publish Year: 2014

Match Overview

Rank	Source	Words	Similarity
1	Crossref	52 words D.P. Al-Adra, R.S. Gill, S.J. Axford, X. Shi, N. Kneteman, S.-S. Liau. "Treatment of unresectable intrahepatic cholangiocar	2%
2	Crossref	37 words Paul C. Lyon, Helen Winter, Karin Herbschleb, Leticia Campo et al. "Long-term radiological and histological outcom...	1%
3	Internet	19 words crawled on 07-Jun-2019 www.bcdha.com	1%
4	Internet	16 words crawled on 27-Mar-2019 link.springer.com	1%
5	Internet	14 words crawled on 12-Jul-2019 www.tandfonline.com	<1%
6	Internet	13 words crawled on 21-Feb-2017 eprints.qut.edu.au	<1%
7	Internet	13 words crawled on 25-Apr-2019 www.myhpnonline.com	<1%
8	Crossref	13 words Svein Dueland, Steinar Aamdal, Michael J. Lind, Hilary Thomas, Marit Liland Sandvold, Jean-Michel Gaullier, Wenche	<1%
9	Crossref	12 words Dan Su, Shun-Chang Jiao, Li-Jie Wang, Wei-Wei Shi, Yan-Yan Long, Juan Li, Li Bai. "Efficacy of nimotuzumab plus g...	<1%
10	Internet	12 words crawled on 09-Sep-2017	<1%

Name of Journal: *World Journal of Gastrointestinal Oncology*

Manuscript NO: 51896

Manuscript Type: SYSTEMATIC REVIEWS

**Yttrium-90 radioembolization for unresectable hepatic metastases of breast cancer:
A systematic review**

Michael Feretis, Andriy Solodky

Abstract

BACKGROUND

Liver metastases secondary to breast cancer are associated with unfavourable prognosis. Radioembolization with yttrium-90 is an emerging option for management of liver metastases of breast cancer when other systemic therapies have failed to achieve disease control. However, unlike the case of other liver tumours

20,400 Results

Any time ▾

[Yttrium-90 Radioembolization of Hepatic Metastases from ...](#)

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4110696>

Jul 25, 2014 · Patient selection criteria for Yttrium-90 radioembolization of hepatic metastases from colorectal cancer. ... A recent systematic review by Saxena et al. ... A systematic review on the safety and efficacy of Yttrium-90 radioembolization for unresectable, chemorefractory colorectal cancer liver metastases.

Cited by: 17 Author: Mihir Raval, Dinesh Bande, Dinesh Bande...

Publish Year: 2014

[Yttrium-90 Radioembolization of Advanced, Unresectable ...](#)

<https://www.sciencedirect.com/science/article/pii/S1051044316301816>

Yttrium-90 Radioembolization of Advanced, Unresectable Breast Cancer Liver Metastases—A Single-Center Experience Author links open overlay panel Claus Christian Pieper MD a Carsten Meyer MD a Kai E. Wilhelm MD a Wolfgang Block PhD a Jennifer Nadal MSc b Hojjat Ahmadzadehfar MD c Winfried Albert Willinek MD a Hans Heinz Schild MD a

Cited by: 13 Author: Claus Christian Pieper, Carsten Meyer, K...

Publish Year: 2016

[Yttrium-90 Microspheres: A Review of Its Emerging Clinical ...](#)

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4439837>

Dec 19, 2014 · Saxena A, Kapoor J, Meteling B, Morris DL, Bester L. Yttrium-90 radioembolization for unresectable, chemoresistant breast cancer liver metastases: a large single-center experience of 40 patients. Ann Surg Oncol. 2014; 21:1296–1303.

Cited by: 19 Author: Natthida Khajornjiraphan, Nyein Aye Thu,...

Publish Year: 2015

[Yttrium-90 Radioembolization for Unresectable ...](#)

<https://link.springer.com/article/10.1245/s10434-013-3436-1>

Dec 15, 2013 · There are a paucity of data on the treatment of unresectable, chemoresistant breast cancer liver metastases (BRCLM) with yttrium-90 (Y90) radioembolization. Methods Forty patients underwent resin-based Y90 radioembolization for unresectable, chemoresistant BRCLM between 2006 and 2012 in a single institution.

Cited by: 27 Author: Akshat Saxena, Akshat Saxena, Jada Ka...



24,500 Results

Any time ▾

Yttrium-90 Radioembolization of Hepatic Metastases from ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4110696>

Jul 25, 2014 · **Yttrium-90 radioembolization** as a salvage treatment for **chemotherapy-refractory disease**. A recent systematic review by Saxena et al. (n = 979) reported a median time to intrahepatic progression of 9 months and a median overall survival of 12 months, the overall acute toxicities ranged from 11 to 100%...

Cited by: 17

Author: Mihir Raval, Dinesh Bande, Dinesh Bande...

Publish Year: 2014

Yttrium-90 Radioembolization of Advanced, Unresectable ...

<https://www.sciencedirect.com/science/article/pii/S1051044316301816>

Surgery as the only curative treatment option of LdBm is feasible in only 10%–20% of patients (3). **Yttrium-90 transarterial radioembolization (TARE)** has been evaluated for palliative treatment of therapy-refractory LdBm in several studies with promising results (4–10).

Cited by: 13

Author: Claus Christian Pieper, Carsten Meyer, K...

Publish Year: 2016

Yttrium-90 Radioembolization for Unresectable ...

<https://link.springer.com/article/10.1245/s10434-013-3436-1> ▾

Dec 15, 2013 · **Keywords**. **Yttrium-90 (Y90) radioembolization** is a promising treatment option for **unresectable, chemoresistant liver tumors**. It has shown promise across a range of tumor types. 9, 10, 11 Several prior studies have demonstrated that **Y90 radioembolization** may be a ...

Cited by: 27

Author: Akshat Saxena, Akshat Saxena, Jada Ka...

Publish Year: 2014

Yttrium-90 radioembolization for unresectable metastatic ...

europepmc.org/abstract/MED/29496075 ▾

Apr 01, 2018 · **CONCLUSIONS:90Y radioembolization** can be used as an alternative therapy for **unresectable liver metastases of NETs**, with an improved **survival rate and tumor response**. This treatment is also effective for patients who have undergone unsuccessful TARE/TACE therapy and for the relief of **symptoms** in patients with **carcinoid syndrome**.

Cited by: 7

Author: Zhongzhi Jia, Weiping Wang

Publish Year: 2018